The therapeutic effects of pegasys in chronic hepatitis B patients with low-level ALT
10.3760/cma.j.issn.1003-9279.2013.03.012
- VernacularTitle:派罗欣对ALT低水平的慢性乙型肝炎疗效观察
- Author:
Yun-Song QIAN
1
;
Ling LI
Author Information
1. 315010,宁波市第二医院消化四科
- Keywords:
Pegasys;
Hepatitis B,chronic;
Alanine transaminase
- From:
Chinese Journal of Experimental and Clinical Virology
2013;27(3):196-198
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the therapeutic effects of Pegasys (pegylated interferon α-2a)in chronic hepatitis B (CHB) patients with low-level alanine transarninase (ALT) ＜ 2 × upper limit of normal (ULN).Methods One hundred and seven CHB patients were randomized enrolled including 52 with ALT ＜ 2 × ULN and liver tissues inflammation activity≥ G2 as observational group and 55 with ALT ＞ 2 × ULN as control group.All the enrolled patients received pegasys treatment for 48 weeks and the responses between two groups were compared.Measurement data were analyzed using t test and numeration data were analyzed using chi square test.Results The reductions of HBV DNA in observational group at different time points were all less than control group (all P ＜ 0.05).At the end of treatment,the HBV DNA negative rate,HBeAg seroconversion rate and HBsAg loss rate in the observational group were 51.9％,48.8％ and 1.9％,respectively,which were all lower than control group (67.3％,66.7％ and 7.3％,respectivley) (all P ＜ 0.05).The ALT normalization rates of two groups were 75％ and 76.4％ (P ＞ 0.05).Conclusion Pegasys is efficient for CHB patients with ALT ＜ 2 × ULN and liver tissues inflammation activity ≥ G2,while it is still inferior to those with ALT ＞ 2 × ULN.
